Search This Blog

Monday, June 3, 2024

'Rafah border crossing can't reopen unless Israel forces quit Gaza side, Egypt says'

 The Rafah border crossing critical to aid deliveries into Gaza from Egypt cannot operate again unless Israel relinquishes control and hands it back to Palestinians on the Gaza side, Egyptian Foreign Minister Sameh Shoukry said on Monday.

Last month, Israel seized Gaza's entire border with Egypt including the crossing during its offensive against Hamas in the city of Rafah. The crossing also represents the only lifeline to the outside world for the 2.3 million population in the Israeli-besieged territory.

"It is difficult for the Rafah crossing to continue operating without a Palestinian administration," Shoukry told a press conference with his Spanish counterpart in Madrid.

Shoukry said the 1979 Egyptian-Israeli peace treaty remained "a solid base for security and stability in the region and everyone must consider and take measures responsibly to preserve this important treaty".

His comments came amid rising tensions after the death of an Egyptian soldier last week in an exchange of fire with Israeli forces who Egyptian security sources said crossed a boundary line while pursuing and killing several Palestinians.

Two Egyptian security sources said a meeting on Sunday of U.S., Egyptian and Israeli officials was positive despite there being no agreement on reopening of the crossing. Egypt's delegation at the meeting said it would be open to European monitors at the border to oversee its operation by Palestinian authorities if Palestinian authorities agreed to resume work.

Israeli Defence Minister Yoav Gallant said on Sunday Israeli forces were seeking to destroy tunnels between Gaza and Egypt used by Hamas to smuggle in weapons, or possibly as a means to escape the war. Egypt has denied the existence of such tunnels.

Under their peace treaty, Egypt and Israel have cooperated closely on security issues around the borders between Israel, Egypt's Sinai Peninsula and Gaza. They jointly upheld a blockade of Gaza after Hamas seized control of the territory in 2007.

Shoukry also called for Hamas and Israel to accept the current proposal for a Gaza ceasefire presented by U.S. President Joe Biden, saying that Hamas' initial comments were positive. "We are now waiting for the Israeli response," he said.

An aide to Prime Minister Benjamin Netanyahu said on Sunday Israel had accepted the framework deal for winding down the Gaza war, but described it as flawed and in need of much more work.

https://www.yahoo.com/news/rafah-border-crossing-cant-reopen-103955752.html

UN officials urge all countries to recognise Palestinian state

 A group of United Nations officials called on Monday for all countries to recognise a Palestinian state to ensure peace in the Middle East.

The call came less than a week after Spain, Ireland and Norway officially recognised a Palestinian state, prompting anger from Israel, which has found itself increasingly isolated after nearly eight months of war in Gaza.

The officials, including the U.N. Special Rapporteur on the human rights situation in the Palestinian territories, said recognition of a Palestinian state was an important acknowledgement of the rights of the Palestinian people and their struggle towards freedom and independence.

"This is a pre-condition for lasting peace in Palestine and the entire Middle East – beginning with the immediate declaration of a ceasefire in Gaza and no further military incursions into Rafah," they said.

"A two-state solution remains the only internationally agreed path to peace and security for both Palestine and Israel and a way out of generational cycles of violence and resentment."

Israel's Foreign Ministry did not respond immediately to a request for comment.

With their recognition of a Palestinian state, Spain, Ireland and Norway said they sought to accelerate efforts to secure a ceasefire in Israel's war with Hamas in Gaza.

The three countries say they hope their decision will spur other European Union states to follow suit. Denmark's parliament later rejected a proposal to recognise a Palestinian state.

Israel has repeatedly condemned moves to recognise a Palestinian state, saying they bolster Hamas, the militant Islamist group that led the deadly Oct. 7 attack on Israel which sparked the Israeli offensive in the Gaza Strip.

https://www.yahoo.com/news/un-experts-urge-countries-recognise-100240393.html

Moderna-Merck skin cancer vaccine shows survival benefit in long-term study

 Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.

Detailed data on Monday from the 157-patient trial showed that after two and a half years, melanoma patients that had received the cancer vaccine combination showed an overall survival rate of 96%, compared with 90.2% with Keytruda alone.

About 75% of the patients on the vaccine combination had recurrence-free survival, compared with 55.6% on Keytruda alone.

The latest data offered more evidence of the vaccine's durability, after a December report that showed a 49% reduction in the risk of recurrence or death among patients who were on the vaccine combination versus Keytruda alone, with a median follow-up of nearly three years.

Moderna and Merck's collaboration is one of the several in the industry that are combining powerful drugs to use the immune system for targeting cancer with the mRNA vaccine technology, which carries instructions for cells to make specific proteins.

Merck and Moderna, which have been collaborating since 2016, are also conducting a late-stage study of their vaccine and Keytruda combination.

https://www.yahoo.com/news/moderna-merck-skin-cancer-vaccine-122332754.html

Mexico president-elect will have to boost tax take to pay for social programs

 Mexican president-elect Claudia Sheinbaum will face the unenviable task of making good on campaign promises to boost social programs even after an election-year spending binge by her predecessor lifted the budget deficit to its highest since the 1980s.

After winning investors' confidence with tight spending policies for most of his term, leftist President Andres Manuel Lopez Obrador loosened the purse strings in his final year in office to finish flagship infrastructure projects and cover a surge in welfare programs for Mexico's poor. That boosted the deficit to 5.9% of gross domestic product in 2024, from 4.3% in prior years.

Those moves will force Sheinbaum's incoming administration to either hold the line on spending, or risk a hit to Mexico's creditworthiness.

Lopez Obrador's finance minister, Rogelio Ramirez de la O, is set to join Sheinbaum's cabinet for some time. "It gives a lot of peace of mind in terms of the economy, and that will smooth the transition," the outgoing president said.

The solution for Latin America's second-largest economy, according to economists, analysts, and former top government officials, is some form of tax overhaul which would boost government revenues – despite Mexico's next leader saying she has no plans to raise taxes.

Sheinbaum handily won Sunday's election on a platform to expand her predecessor's popular social programs, including increasing pensions for senior citizens and student scholarships.

MARKET JITTERS

In her victory speech, Sheinbaum promised to continue with Lopez Obrador's policy of "republican austerity", maintain financial and fiscal discipline, and respect the autonomy of the Bank of Mexico.

Despite those pledges, the election sent shockwaves through the market as the ruling Morena party and its coalition partners look primed for a congressional super-majority, which would make constitutional change easier and diminish checks and balances.

The final seat counts are still being tallied, but Mexico's peso fell as much as 4% against the dollar before recovering some losses and trading down 3% while Mexico's main stock index fell 3% on Monday.

In February, Lopez Obrador proposed sweeping constitutional reforms, including measures to overhaul the judiciary, electoral law, pensions, and environmental regulations.

"Some bills are perceived as leading to institutional erosion and weakening the current checks and balances, and several are not viewed as market friendly. With full control of the House, and for practical purposes likely the Senate as well, the probability that a significant part of this broad agenda is approved increased significantly," said Alberto Ramos, chief Latin America economist at Goldman Sachs.

NO FISCAL REFORM IN SIGHT

Sheinbaum, who will take office as Mexico's first woman president in October, has said she will look to cut red tape and improve the efficiency of tax collection at customs, among other proposals, but is not planning fiscal reform.

"I'm not thinking about a deep tax reform, I think there are still many opportunities for (tax) collection," Sheinbaum said days prior to the election at a televised forum.

Just the cost of pensions, servicing public debt and federal government transfers to support Mexican states accounted for more than half of the country's 9.07 trillion pesos ($535 billion) budget this year, while indebted state oil firm Pemex is no longer the cash cow it was for previous Mexican governments.

"The challenge is big," said former finance minister Ernesto Cordero. "If they want to finance their proposals and their way of seeing the country, they need to think about how they are going to do it."

Still, the possibility of a super majority could make the politically unpalatable changes needed to boost tax take easier to push through.

PRESSURED FROM ALL SIDES

With Mexico's public finances pressured from all sides and the current avenues for boosting much-needed tax take drying up, experts suggest changing the inefficient way properties and cars are taxed, tweaks to taxes on corporate profits, "green taxes," and royalties on Pemex.

"The idea of tax reform is a debate we should have," said political analyst Fernando Dworak. "Everyone is talking about what they are going to do, but nobody mentions how they are going to pay for it."

Neither does it look like economic growth will help plug any gap, with the Bank of Mexico projecting a lackluster 1.5% rise in GDP for next year.

The last fiscal reform dates back a decade, when former President Enrique Pena Nieto hiked taxes for the highest earners and new levies were imposed on soft drinks, junk food, and financial market profits.

During his administration Lopez Obrador managed to increase tax revenue by clamping down on evasion and forcing big corporations to settle tax disputes worth billions of dollars. That brought a 48% rise in tax revenue in nominal terms from 2018 through 2023, but experts warn it is not a repeatable policy.

"Six years ago there was room for savings on the spending side and improvements in the state's ability to collect taxes," said former Bank of Mexico deputy governor Gerardo Esquivel last month at a roundtable hosted by the National Autonomous University of Mexico.

Now, Esquivel added, the new president will have to find different solutions to a worsening budget conundrum.

Mexico's tax take still lags far behind its peers, amounting to only 16.9% of GDP in 2022, far below the 34% average for member nations of the Organization for Economic Co-operation and Development, of which Mexico is a member. Even more striking, Mexico was below the average of 21.5% among Latin America countries.

Political scientist Dworak cautioned that without the means to pay for an expansion of social program, the president-elect's promises are wishful thinking, something akin to "letters to Santa Claus."

https://www.yahoo.com/news/analysis-mexicos-next-president-boost-120802073.html

Gilead, Arcus Regimen Significantly Reduced Risk of Death in 3rd-line Metastatic Colorectal Cancer

 

  • In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial
 Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC). These results will be presented today during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Zev A. Wainberg, M.D., MSc, Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-9 trial (Abstract 3508).

Immutep to Collaborate with MSD to Evaluate Combo in Pivotal Phase III Trial

 

  • Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)
  • TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy
  • Under the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDA
  • Immutep retains commercial rights to efti
  • Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet medical need, across all levels of PD-L1 expression (negative, low, and high)

Ideaya Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update

 

  • 75% eye preservation rate (9 of 12 enucleation patients)
  • ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months
  • Company-sponsored Phase 2 Neoadjuvant UM: Over 40 patients enrolled, and for the 8 patients with ≥4-months of darovasertib observed median tumor shrinkage of 72% by volume change and eye preserved for the majority of enucleation patients
  • Targeting Type C meeting with the FDA in H2 2024 for guidance on potential registrational trial for darovasertib in neoadjuvant UM setting
  • Projected global annual incidence of primary UM is ~8,000 to ~10,000 patients